Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics is well positioned for long-term success, with a strong pipeline and a sound financial position, evident from the recent positive results from its clinical trials and the successful public offering in December 2025. There are potential manufacturing constraints and regulatory risks, but the company's promising partnerships with the likes of Alnylam Pharmaceuticals and successful resolution of a FDA clinical hold show its resilience in overcoming obstacles and driving its innovative platform forward. The dynamic and competitive nature of the gene therapy market adds uncertainty, but Tenaya's established presence in the realm of heart disease treatments and continued advancements in its platforms make it a promising investment opportunity.

Bears say

Tenaya Therapeutics is a clinical-stage biotechnology company that is working on therapies for rare genetic disorders and heart conditions, with a specific focus on cellular regeneration, gene therapy, and precision medicine. Despite promising initial clinical data from their programs, comparisons between other companies in the sector and lack of clear superiority make it difficult to determine the potential success of Tenaya's products. Additionally, there are risks associated with the manufacturing and commercialization of AAV-based gene therapy products, which could impact the company's potential success.

Tenaya Therapeutic (TNYA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.